Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe parkinsonian's patients;Fluctuaciones y disquinesias como complicación precoz de la levodopaterapia en pacientes parkinsonianos graves

Neurologia

Volumn 18, Issue 3, 2003, Pages 162-165

  Vaamonde, J ^a   Ibanez R ^a   Gudin M ^a   Hernandez A ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Motor complications; Parkinson's disease; Severity

Indexed keywords

APOMORPHINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DYSKINESIA; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSON DISEASE; RISK FACTOR; STRIATONIGRAL DEGENERATION;

AGED; ANTIPARKINSON AGENTS; APOMORPHINE; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS;

EID: 0037398521     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Marsden CD, Parkes JD, Quinn N. Fluctuation of disability in Parkinson'disease: In: Marsden CD, Fhan S, editores. Movement disorders. London: Butterworths Scientific, 1982;96-122.
2. Vaamonde J, Ibáñez R, Grandas F. Tratamiento farmacológico de la enfermedad de Parkinson. En: Jiménez-Jiménez FJ, Luquin MR, Molina JA, editores. Tratado de los trastornos del movimiento. Madrid, 1998;325-58.
3. Mouradian MM, Juncos JL, Fabrini G, Chase TN. Motor fluctuations in Parkinson'disease. Pathogenic and therapeutic studies. Ann Neurol 1987;22:475-9.
4. Obeso J, Luquin R, Vaamonde J, Grandas F, Martínez-Lage JM. The pathophysiology and treatment of motor fluctuations and dyskinesias in Parkinson's disease: infusion studies. En: Fhan S, Marsden CD, Calne D, Golstein M, editores. Recent developments in Parkinson'disease. New Jersey: MacMillan Healthcare Information, 1991.
5. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
6. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomised trial of ropinirol and bromocriptine in early Parkinson's disease. Neurology 1999;53:364-70.
7. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 study group. N Engl J Med 2000;342:1484-91.
8. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-23.
9. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson'disease. Neurology 1995;45:13-21.
10. Shannon K, Bennett JP, Friedman JH. Efficacy of pramipexol, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997;49:724-8.
11. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications-results of a double-blind levodopa controlled trial. Drugs 1998;55:23-30.
12. Maratos EC, Jackson MJ, Pearce RKB, Jenner P. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-Dopa combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Mov Disord 2001;16:631-61.
13. Bedard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesias in MPTP-parkinsonian monkeys: correlations with H-spepirone binding. Brain Res 1986;379:294-9.
14. Rodriguez M, Macias R. Fisiología del sistema dopaminérgico nigroestrialtal: implicaciones en el tratamiento de la enfermedad de Parkinson. Neurologia 2002;17(Suppl.1):28-36.
15. Tedroff J, Ekesbo A, Rydin E, Langstrom B, Hagberg G. Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol 1999;46:359-65.
16. Frey K A. The neurochemistry of therapeutics: levodopa pharmacodinamics in Parkinson'disease. Ann Neurol 2001;49:285-6.
17. De La Fuente-Fernández R, Lu Jing-Qiang, Sossi V, Jivan S, Schulzer M, Holden J, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
18. Nutt J. The case for and concerns about continuous dopamine stimulation in Parkinson's disease. J Neural Transm 1988;27(Suppl):35-54.
19. Obeso J, Luquin R, Vaamonde J. Continuous dopaminergic stimulation for Parkinson's disease. Can J Neuol Sci 1987;14:488-92.
20. Fox S, Henry B, Hill M, Peggs MS, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of alpha 2 adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-50.
21. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.
22. Schrag A, Kingsley D, Phatouros C, Mathias CJ, Lees AJ, Daniel SE, et al. Clinical usefulness of magnetic resonance imaging in multisystem atrophy. J Neurol Neurosurgery Psychiatry 1998;65:65-71.